Render Target: SSR
Render Timestamp: 2024-12-19T21:28:58.383Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:56:14.064
Product last modified at: 2024-12-17T18:59:06.270Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

PARG (D4E6X) Rabbit mAb #66564

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H Mk
    SENSITIVITY Endogenous
    MW (kDa) 130
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    PARG (D4E6X) Rabbit mAb recognizes endogenous levels of total PARG protein. This antibody specifically recognizes PARG isoform 1 (UniProt #Q86W56-1) and does not recognize other PARG isoforms.

    Species Reactivity:

    Human, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human PARG protein.

    Background

    Poly (ADP-ribose) glycohydrolase (PARG) is an enzyme that hydrolyzes poly (ADP-ribose) (PAR) formed by members of the PAR polymerase (PARP) enzyme family. Poly (ADP)-ribosylation is a post-translational modification that is catalyzed by PARP proteins. This modification involves polymerization of ADP-ribose from NAD+ to target proteins, such as histones and transcription factors, and plays a wide range of biological roles, including the response to DNA damage and transcriptional regulation (1,2). The mammalian PARG enzyme that catalyzes the removal of this modification exists as multiple isoforms. PARG isoforms 1-3 shuttle between the nucleus and cytoplasm and are responsible for most of the PARG activity. The smaller isoforms 4 and 5 reside in the cytoplasm (3-5). Research studies link altered PAR metabolism to inflammatory and autoimmune diseases, as well as neuronal degeneration (6-8). PARG inhibitors that increase PAR levels may sensitize cells to cancer treatments (e.g., cisplatin) and may help in the development of cancer therapies (9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.